Introduction: Cardiovascular diseases are the leading cause of death globally, responsible for 17.9 million deaths annually. In Mongolia, as of 2023, CVDs account for 43.7% of total mortality. In line with the global trend of integrating traditional medicine into modern healthcare, Mongolia has increased research into natural, plant-based remedies.
This study focuses on evaluating and standardizing selected natural raw materials commonly used in traditional prescriptions for cardiovascular conditions. The goal is to assess their quality, ensure safety, and support their scientific validation for modern clinical use. The findings aim to contribute to the development of effective, evidence based traditional medicines aligned with national health policy priorities. Methods: All of three medicinal plants (Santalum album L., Myristica fragrans Hountt., Choerospondias axillaris Roxb.) used in this study were purchased from the Chinese. The dried raw materials of all selected plants were authenticated and analyzed using the standards outlined in the Pharmacopoeia of the people’s republic of China 2020 and Japanese pharmacopoeia 18^th edition.
The sample solution showed a spot at the level as the standard santalol, with an Rf value of 0.35. The total volatile oil content of the santalol residue was found to be 3.3% The sample solution showed a spot at the level as the standard myristicin, with an Rf value of 0.6±0.0001 The dehydrodiisoeugenol content in Myristica fragrans was determined using High-Performance Liquid Chromatography (HPLC) and the result was /0.17±0.0001/ % The sample solution showed a spot at the level as the standard gallic acid, with an Rf value of 0.7±0.0001 The gallic acid content in Choerospondias axillaris was determined using High-Performance Liquid Chromatography (HPLC) and the result was /0.097±0.0001/%. Conclusion According to our research, all raw materials in the Santalum album, Myristica fragrans, Choerospondias axillaris preparation meet the requirements of the Pharmacopoeia of the People’s of China.

Introduction: Inula helenium L. is a medicinal plant widely used in traditional Mongolian and Tibetan medicine. Its roots and rhizomes contain active compounds, including sesquiterpene lactones (alantolactone and isoalantolactone), inulin, flavonoids, and essential oils, with anti-inflammatory, antimicrobial, and immunomodulatory properties. This study evaluates the quality of Inula helenium L. roots and quantifies their key active compounds in accordance with pharmacopoeial standards. Methods: The roots of Inula helenium L. cultivated in the Medicinal Plant Botanical Garden of Monos Group were used as raw material. Physicochemical parameters, including moisture, total ash, acid-insoluble ash, and extractive values, were determined according to pharmacopoeial methods. Qualitative analysis was carried out using color reactions for polysaccharides and thin-layer chromatography for the identification of sesquiterpene lactones. Quantitative analysis was performed using spectrophotometry for total polysaccharides and high-performance liquid chromatography (HPLC) for the determination of alantolactone and isoalantolactone. Conclusion The physicochemical parameters of Inula helenium L. root were standardized, with total inulin content determined as 47.13±0.45%, alantolactone as 1.41±0.02%, and isoalantolactone as 1.33±0.02%. Analytical methods for inulin, alantolactone, and isoalantolactone were validated according to ICH Q2(R2) guidelines, confirming the possibility of updating the MNS standard or developing a manufacturer’s pharmacopoeial monograph based on these validated methods.

Introduction: Doxylamine succinate has an anticholinergic effect and is an antihistaminic active compound. Drugs containing this active compound relieve the symptoms of allergies, allergic rhinitis, and the common cold and treat short-term insomnia.
In Mongolia’s National Drug Registration list, five doxylamine succinate-based tablets are cataloged, and imported from France, Turkey, Slovenia, India, and South Korea. Doxylamine succinate tablets have not yet been introduced into production within domestic industries. Therefore, we have developed tablets featuring novel technology and standardization. Purpose: This study aims to investigate the research on technology and standardization of doxylamine succinate tablets and assess the viability of their introduction into domestic manufacturing. Methods: For the technological study, the main raw material was purchased from Apollo Healthcare Ltd. in China, and tablets of 5 versions were obtained by wet granulation compression method. Carr’s index and Hausner’s ratio of the granules were calculated according to the British pharmacopeia.
For the standardization study, we purchased standards from Sigmaaldrich® and determined physical, and chemical parameters by Mongolian National Pharmacopoeia (MNP) and United States Pharmacopoeia (USP). Results: Version 2’s Carr’s index was 8.15%, and Hausner’s ratio was 1.09, indicating that the tablet’s compressibility and flowability of granules are excellent. Moreover, version 3’s Carr’s index was 10.70%, and Hausner’s ratio was 1.12, which indicates the tablet’s compressibility and flowability of granules are good.
Both versions above met the requirements as appearance, friability, breaking force, weight variation limits, dissolution, and assay according to USP and MNP. Despite that, only version 3 conformed to disintegration for requirements outlined in the MNP. Conclusion The assay determination method has been validated following ICH guidelines and the quality attributes of the tablet have been specified. Based on the results obtained, version 3 of the experimental tablets is deemed feasible for introduction into production.